NCT02018861 2023-09-28
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Incyte Corporation
Phase 1/2 Completed
Incyte Corporation
Bristol-Myers Squibb